Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Onatasertib - Celgene

Drug Profile

Onatasertib - Celgene

Alternative Names: ATG 008; CC 223

Latest Information Update: 29 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celgene Corporation
  • Developer Antengene Corporation; Celgene Corporation
  • Class Antineoplastics; Pyrazines; Pyridines; Small molecules
  • Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Liver cancer; Non-small cell lung cancer; Solid tumours
  • Phase I/II Multiple myeloma; Non-Hodgkin's lymphoma
  • Phase I Diffuse large B cell lymphoma
  • No development reported Prostate cancer

Most Recent Events

  • 12 Dec 2023 Celgene terminates a phase I trial in Diffuse large B-cell lymphoma (Combination therapy, Second-line therapy or greater) in Canada, Italy, USA and France (PO) as the trial was replaced with another clinical trial (NCT02031419)
  • 17 Nov 2023 Updated efficacy data from the TORCH-2 phase I/II trial in Solid tumours released by Antengene Corporation
  • 25 Aug 2023 Updated efficacy data from the TORCH-2 phase I/II trial in Solid tumours released by Antengene Corporation
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top